Sign in
Back
Clarithromycin–Rifampin-Based Treatment for Nontuberculous Mycobacteria Infections in Immunocompromised Patients who Require Concomitant CYP-Metabolized Medications
Journal article   Open access  Peer reviewed

Clarithromycin–Rifampin-Based Treatment for Nontuberculous Mycobacteria Infections in Immunocompromised Patients who Require Concomitant CYP-Metabolized Medications

Isabel H Gonzalez-Bocco, Muneerah M Aleissa, Eric Zhou, Jennifer Manne-Goehler, Sophia Koo, Matthew P Cheng and Francisco M Marty
Open forum infectious diseases, Vol.9(1), pp.ofab582-ofab582
01/01/2022
DOI: https://doi.org/10.1093/ofid/ofab582
PMID: 34988253

Abstract

nontuberculous mycobacteria clarithromycin immunocompromised host complex
Abstract Clarithromycin (CYP inhibitor) can be used instead of azithromycin for nontuberculous mycobacteria therapy in patients requiring CYP substrates to mitigate rifampin’s CYP induction. We found no differences in adverse events (10/13 vs 14/17; P = .73), drug intolerability (1/5 vs 4/11; P = 1), or 90-day mortality (0/13 vs 1/17; P = 1) in patients receiving clarithromycin vs azithromycin.
url
https://doi.org/10.1093/ofid/ofab582View
Published (Version of record) Open

Metrics

1 Record Views

Details